EVALUATION OF DRUG-DRUG INTERACTIONS (DDI) BETWEEN OATP1B/CYP3A INHIBITORS AND [FAM-] TRASTUZUMAB DERUXTECAN (T-DXD, DS 8201) IN HER2-EXPRESSING SOLID TUMORS.

Kamiyama E.; Garimella T.; Bang Y.; Takahashi S.; LaCreta F.; Ishizuka H.; Abutarif M.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >EVALUATION OF DRUG-DRUG INTERACTIONS (DDI) BETWEEN OATP1B/CYP3A INHIBITORS AND [FAM-] TRASTUZUMAB DERUXTECAN (T-DXD, DS 8201) IN HER2-EXPRESSING SOLID TUMORS.

【24h】

EVALUATION OF DRUG-DRUG INTERACTIONS (DDI) BETWEEN OATP1B/CYP3A INHIBITORS AND [FAM-] TRASTUZUMAB DERUXTECAN (T-DXD, DS 8201) IN HER2-EXPRESSING SOLID TUMORS.

机译：在HER2-表达实体瘤中评价oATP1B / CYP3A抑制剂与[FAM-曲妥珠单抗亚苏克西（T-DXD，DS 8201）的药物 - 药物相互作用（DDI）。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2020年第s1期|共1页
作者
Kamiyama E.; Garimella T.; Bang Y.; Takahashi S.; LaCreta F.; Ishizuka H.; Abutarif M.;
展开▼
作者单位

Daiichi Sankyo Tokyo Japan;

Daiichi Sankyo Basking Ridge NJ USA;

Seoul Natl Univ Seoul South Korea;

Japanese Fdn Canc Res Canc Inst Hosp Tokyo Japan;

Daiichi Sankyo Basking Ridge NJ USA;

Daiichi Sankyo Tokyo Japan;

Daiichi Sankyo Basking Ridge NJ USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. EVALUATION OF DRUG-DRUG INTERACTIONS (DDI) BETWEEN OATP1B/CYP3A INHIBITORS AND [FAM-] TRASTUZUMAB DERUXTECAN (T-DXD, DS 8201) IN HER2-EXPRESSING SOLID TUMORS. [J] . Kamiyama E., Garimella T., Bang Y., Clinical Pharmacology and Therapeutics . 2020,第S1期

机译：在HER2-表达实体瘤中评价oATP1B / CYP3A抑制剂与[FAM-曲妥珠单抗亚苏克西（T-DXD，DS 8201）的药物 - 药物相互作用（DDI）。
2. [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized trial (DESTINY-Breast03) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：[FAM-]曲妥珠单抗（T-DXD; DS-8201A）与预先接受曲妥珠单抗和紫杉烷的患者（T-DXD; DS-8201A）对受试者的ADO-TRASTUZUMAB emtansine（T-DM1）与HER2-阳性，不可切除的和/或转移性乳腺癌：阶段3 ，随机试验（Destiny-Breast03）
3. A phase 3, multicenter, randomized, open-label trial of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：[FAM-] Trastuzumab Deruxtecan（T-DXD; DS-8201A）对HER2低乳腺癌（DESTINY-BRESK04）的选择3
4. In silico evaluation of bioactive compounds: Docking Simulations based Enzyme-Inhibitor Interaction compared with X-ray models [C] . Georgios Vlachopoulos, Athanasios Papakyriakou, George Dalkas, Advances in Computational Methods in Sciences and Engineering 2005 vol.4B; Lecture Series on Computer and Computational Sciences; vol.4B . 2005

机译：在计算机上评估生物活性化合物的方法：与X射线模型相比，基于对接模拟的酶-抑制剂相互作用
5. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti–CTLA-4 antibody in a mouse model [O] . Tomomi Nakayama Iwata, Kiyoshi Sugihara, Teiji Wada, 2012

机译：[Fam-]曲妥珠单抗deruxtecan（DS-8201a）诱导的抗肿瘤免疫作用通过抗CTLA-4抗体在小鼠模型中促进
6. Fam- trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti–CTLA-4 antibody in a mouse model [O] . Tomomi Nakayama Iwata, Kiyoshi Sugihara, Teiji Wada, 2019

机译：通过小鼠模型中的抗CTLA-4抗体促进了抗肿瘤免疫诱导的抗肿瘤免疫力诱导的抗肿瘤免疫力
7. AN EVALUATION OF PREDICTIVE METHODS OF DETERMINING THE EFFECTS OF SOLID-LIQUID PHASE INTERACTIONS ON THE MOVEMENT OF SOLUTES IN SOILS, [R] . routson, r. c. 1970

机译：确定固 - 液相互作用对土壤中溶质运动影响的预测方法的评价，

EVALUATION OF DRUG-DRUG INTERACTIONS (DDI) BETWEEN OATP1B/CYP3A INHIBITORS AND [FAM-] TRASTUZUMAB DERUXTECAN (T-DXD, DS 8201) IN HER2-EXPRESSING SOLID TUMORS.

著录项

相似文献

相关主题

期刊订阅